1. Turning Down the Food Noise.
- Author
-
YOUNG, LAUREN J.
- Subjects
WEIGHT loss ,INGESTION ,PERIPHERAL nervous system ,WEIGHT gain ,REWARD (Psychology) ,GASTROINTESTINAL agents ,GASTRIC inhibitory polypeptide ,PANCREAS ,BLOOD-brain barrier - Abstract
This article explores the development and impact of weight-loss drugs that imitate a hormone called glucagonlike peptide 1 (GLP-1). These drugs, known as GLP-1 receptor agonists, have been successful in reducing appetite and promoting weight loss. Researchers are currently investigating how these drugs affect the brain's regulation of hunger, satisfaction, pleasure, and reward. The drugs seem to influence the brain's response to food, resulting in a decrease in compulsive eating and addictive behaviors. The article emphasizes the potential of these drugs in treating obesity and provides insights into the biology underlying their effects. GLP-1-based medications like Wegovy and Ozempic show promise in reducing cravings for food and other addictive substances. These drugs target GLP-1 receptors in the brain, which are involved in reward pathways and motivation. Studies suggest that GLP-1 medications may be effective in treating addiction, including opioid use disorder. Furthermore, these drugs are being researched for their potential to treat other conditions such as liver disease, Alzheimer's, Parkinson's, depression, and cancer. However, the effectiveness of GLP-1 medications can vary among individuals, and some individuals may experience side effects like nausea and diarrhea. Overall, these drugs are reshaping the understanding of obesity and addiction as intricate neurometabolic diseases for researchers and healthcare professionals. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF